Roche Holding AG (ROG) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.296x

Based on the latest financial reports, Roche Holding AG (ROG) has a cash flow conversion efficiency ratio of 0.296x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF11.23 Billion ≈ $14.20 Billion USD) by net assets (CHF37.88 Billion ≈ $47.89 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Roche Holding AG - Cash Flow Conversion Efficiency Trend (1998–2025)

This chart illustrates how Roche Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Roche Holding AG Competitors by Cash Flow Conversion Efficiency

Annual Cash Flow Conversion Efficiency for Roche Holding AG (1998–2025)

The table below shows the annual cash flow conversion efficiency of Roche Holding AG from 1998 to 2025.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CHF37.88 Billion
≈ $47.89 Billion
CHF17.83 Billion
≈ $22.54 Billion
0.471x -15.29%
2024-12-31 CHF36.16 Billion
≈ $45.72 Billion
CHF20.09 Billion
≈ $25.40 Billion
0.556x +14.84%
2023-12-31 CHF33.26 Billion
≈ $42.05 Billion
CHF16.09 Billion
≈ $20.35 Billion
0.484x -13.41%
2022-12-31 CHF32.02 Billion
≈ $40.48 Billion
CHF17.89 Billion
≈ $22.62 Billion
0.559x -22.99%
2021-12-31 CHF28.34 Billion
≈ $35.84 Billion
CHF20.57 Billion
≈ $26.00 Billion
0.726x +58.93%
2020-12-31 CHF39.77 Billion
≈ $50.28 Billion
CHF18.16 Billion
≈ $22.96 Billion
0.457x -26.84%
2019-12-31 CHF35.87 Billion
≈ $45.35 Billion
CHF22.39 Billion
≈ $28.30 Billion
0.624x -5.14%
2018-12-31 CHF30.37 Billion
≈ $38.39 Billion
CHF19.98 Billion
≈ $25.26 Billion
0.658x +5.89%
2017-12-31 CHF29.01 Billion
≈ $36.67 Billion
CHF18.02 Billion
≈ $22.79 Billion
0.621x +9.36%
2016-12-31 CHF26.40 Billion
≈ $33.38 Billion
CHF15.00 Billion
≈ $18.97 Billion
0.568x -13.20%
2015-12-31 CHF23.30 Billion
≈ $29.46 Billion
CHF15.25 Billion
≈ $19.28 Billion
0.655x -11.42%
2014-12-31 CHF21.56 Billion
≈ $27.26 Billion
CHF15.93 Billion
≈ $20.14 Billion
0.739x -0.48%
2013-12-31 CHF21.24 Billion
≈ $26.85 Billion
CHF15.77 Billion
≈ $19.94 Billion
0.743x -17.22%
2012-12-31 CHF16.73 Billion
≈ $21.15 Billion
CHF15.01 Billion
≈ $18.97 Billion
0.897x +0.28%
2011-12-31 CHF14.48 Billion
≈ $18.31 Billion
CHF12.95 Billion
≈ $16.38 Billion
0.894x -27.27%
2010-12-31 CHF11.66 Billion
≈ $14.74 Billion
CHF14.34 Billion
≈ $18.13 Billion
1.230x -31.40%
2009-12-31 CHF9.41 Billion
≈ $11.90 Billion
CHF16.88 Billion
≈ $21.34 Billion
1.793x +692.39%
2008-12-31 CHF53.82 Billion
≈ $68.05 Billion
CHF12.18 Billion
≈ $15.40 Billion
0.226x +2.83%
2007-12-31 CHF53.31 Billion
≈ $67.39 Billion
CHF11.73 Billion
≈ $14.83 Billion
0.220x -0.29%
2006-12-31 CHF46.81 Billion
≈ $59.19 Billion
CHF10.33 Billion
≈ $13.06 Billion
0.221x -7.67%
2005-12-31 CHF41.74 Billion
≈ $52.77 Billion
CHF9.97 Billion
≈ $12.61 Billion
0.239x +8.46%
2004-12-31 CHF33.29 Billion
≈ $42.09 Billion
CHF7.33 Billion
≈ $9.27 Billion
0.220x -11.41%
2003-12-31 CHF29.16 Billion
≈ $36.87 Billion
CHF7.25 Billion
≈ $9.17 Billion
0.249x +552.72%
2002-12-31 CHF25.77 Billion
≈ $32.58 Billion
CHF982.00 Million
≈ $1.24 Billion
0.038x -74.64%
2001-12-31 CHF33.87 Billion
≈ $42.82 Billion
CHF5.09 Billion
≈ $6.43 Billion
0.150x +22.90%
2000-12-31 CHF32.04 Billion
≈ $40.50 Billion
CHF3.92 Billion
≈ $4.95 Billion
0.122x +112.35%
1999-12-31 CHF30.00 Billion
≈ $37.93 Billion
CHF1.73 Billion
≈ $2.18 Billion
0.058x -63.69%
1998-12-31 CHF22.82 Billion
≈ $28.84 Billion
CHF3.62 Billion
≈ $4.57 Billion
0.159x --

About Roche Holding AG

SW:ROG Switzerland Drug Manufacturers - General
Market Cap
$279.33 Billion
CHF220.94 Billion CHF
Market Cap Rank
#60 Global
#1 in Switzerland
Share Price
CHF320.70
Change (1 day)
+0.79%
52-Week Range
CHF246.30 - CHF374.00
All Time High
CHF374.00
About

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more